Deutsch | English | Français - CHF | EUR | USD
Analysen | Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
 Sie befinden sich in - Home - Fachinformation zu Xalkori®
Fachinformation zu Xalkori®:Pfizer AG
Vollst. FachinformationDDDÄnderungen anzeigenDrucken
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info.
L01XE16 - CrizotinibATC-DDD Version 2016. Source: WHO
L - Antineoplastic and Immunomodulating Agents

This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.

L01 - Antineoplastic Agents

Combination products are classified in L01XY - Combinations of antineoplastic agents.
Detoxifying agents used in connection with high dose treatment of antineoplastic agents are classified in V03AF (e.g. calcium folinate)

No DDDs have been established because of highly individualised use and wide dosage ranges. The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.
The consumption of the antineoplastic agents is in some countries measured in grams. This is recommended as a method to be used internationally for these particular agents.

L01X - Other Antineoplastic Agents

This group comprises antineoplastic preparations which cannot be classified in the preceding groups.

L01XE - Protein Kinase Inhibitors
 
L01XE16 - Crizotinib
LGPL2017 ywesee.com, Commit-ID
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home